With an overall 5-year survival rate under 6% and a median survival of 6 months, pancreatic cancer is the most devastating human malignancies. Moreover, the almost identical annual incidence and mortality rate makes it the fourth leading cause of cancer-related death in Canada and worldwide. Despite enormous progress in medicine, the survival of patients with pancreatic cancer has not significantly improved over the last 40 years. The main reason for the dismal prognosis of this type of cancer remains the late diagnosis of the disease, hence rendering surgical resection rates exceedingly low in addition to yielding poor clinical response to chemotherapy. This raises the urgent need for the identification of biomarkers to aid in the early detection of pancreatic cancer as well as the development of new and effective treatment strategies. To attempt this goal, a better understanding of the detailed mechanisms of disease pathogenesis is critical. My research program intends to identify and characterize key signaling pathways required for the proliferation and survival of pancreatic cancer cells, two processes deregulated in pancreatic cancer cells as compared to normal cells. Hence, my research program will contribute to deepen our knowledge on fundamental processes involved in pancreatic cancer pathogenesis as well as providing a rationale for new therapeutic strategies for this lethal malignancy.